These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 8573124)

  • 21. Skewing the T-cell repertoire by combined DNA vaccination, host conditioning, and adoptive transfer.
    Jorritsma A; Bins AD; Schumacher TN; Haanen JB
    Cancer Res; 2008 Apr; 68(7):2455-62. PubMed ID: 18381454
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Modifying interleukin-2 concentrations during culture improves function of T cells for adoptive immunotherapy.
    Besser MJ; Schallmach E; Oved K; Treves AJ; Markel G; Reiter Y; Schachter J
    Cytotherapy; 2009; 11(2):206-17. PubMed ID: 19148842
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Complete regression of advanced primary and metastatic mouse melanomas following combination chemoimmunotherapy.
    Kohlmeyer J; Cron M; Landsberg J; Bald T; Renn M; Mikus S; Bondong S; Wikasari D; Gaffal E; Hartmann G; Tüting T
    Cancer Res; 2009 Aug; 69(15):6265-74. PubMed ID: 19622767
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Immune selection and emergence of aggressive tumor variants as negative consequences of Fas-mediated cytotoxicity and altered IFN-gamma-regulated gene expression.
    Liu K; Caldwell SA; Abrams SI
    Cancer Res; 2005 May; 65(10):4376-88. PubMed ID: 15899830
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Preparation of fully activated dendritic cells capable of priming tumor-specific cytotoxic T lymphocytes in patients with metastatic cancer using penicillin-killed streptococcus pyogenes (OK432) and anti-CD40 antibody.
    Kontani K; Teramoto K; Ozaki Y; Sawai S; Tezuka N; Ishida H; Kajino K; Fujino S; Yamauchi A; Taguchi O; Kannagi R; Yokomise H; Ogasawara K
    Oncol Rep; 2007 Apr; 17(4):895-902. PubMed ID: 17342333
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Induction of antitumor immunity by combined immunogene therapy using IL-2 and IL-12 in low antigenic Lewis lung carcinoma.
    Tanaka M; Saijo Y; Sato G; Suzuki T; Tazawa R; Satoh K; Nukiwa T
    Cancer Gene Ther; 2000 Nov; 7(11):1481-90. PubMed ID: 11129290
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Increased susceptibility to immune destruction of B16BL6 tumor cells engineered to express a novel pro-Smac fusion protein.
    Rüttinger D; Li R; Poehlein CH; Haley D; Walker EB; Hu HM; Fox BA
    J Immunother; 2008 Jan; 31(1):43-51. PubMed ID: 18157011
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Immunization with adenoviral vectors carrying recombinant IL-12 and E7 enhanced the antitumor immunity to human papillomavirus 16-associated tumor.
    Jin HS; Park EK; Lee JM; NamKoong SE; Kim DG; Lee YJ; Jun HJ; Han BD; Bae SM; Ahn WS
    Gynecol Oncol; 2005 May; 97(2):559-67. PubMed ID: 15863160
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Concurrent delivery of GM-CSF and B7-1 using an oncolytic adenovirus elicits potent antitumor effect.
    Choi KJ; Kim JH; Lee YS; Kim J; Suh BS; Kim H; Cho S; Sohn JH; Kim GE; Yun CO
    Gene Ther; 2006 Jul; 13(13):1010-20. PubMed ID: 16525479
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A combination hybrid-based vaccination/adoptive cellular therapy to prevent tumor growth by involvement of T cells.
    Savai R; Schermuly RT; Pullamsetti SS; Schneider M; Greschus S; Ghofrani HA; Traupe H; Grimminger F; Banat GA
    Cancer Res; 2007 Jun; 67(11):5443-53. PubMed ID: 17545626
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Archaeosomes induce enhanced cytotoxic T lymphocyte responses to entrapped soluble protein in the absence of interleukin 12 and protect against tumor challenge.
    Krishnan L; Sad S; Patel GB; Sprott GD
    Cancer Res; 2003 May; 63(10):2526-34. PubMed ID: 12750276
    [TBL] [Abstract][Full Text] [Related]  

  • 32. HPV16E7 tumor antigen modified by KDEL sequence induce specific cytotoxic T lymphocytes-dependent antitumor immunity.
    Yin R; Zheng W; Hao F; Yang XC; Zhong BY; Li QJ
    J Dermatol Sci; 2009 Aug; 55(2):116-22. PubMed ID: 19500947
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Lymphotactin cotransfection enhances the therapeutic efficacy of dendritic cells genetically modified with melanoma antigen gp100.
    Xia DJ; Zhang WP; Zheng S; Wang J; Pan JP; Wang Q; Zhang LH; Hamada H; Cao X
    Gene Ther; 2002 May; 9(9):592-601. PubMed ID: 11973635
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Tumor-infiltrating lymphocytes exhibiting high ex vivo cytolytic activity fail to prevent murine melanoma tumor growth in vivo.
    Prévost-Blondel A; Zimmermann C; Stemmer C; Kulmburg P; Rosenthal FM; Pircher H
    J Immunol; 1998 Sep; 161(5):2187-94. PubMed ID: 9725210
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Combining tumor-targeted superantigens with interferon-alpha results in synergistic anti-tumor effects.
    Sundstedt A; Celander M; Hedlund G
    Int Immunopharmacol; 2008 Mar; 8(3):442-52. PubMed ID: 18279798
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The anti-human tumor effect and generation of human cytotoxic T cells in SCID mice given human peripheral blood lymphocytes by the in vivo transfer of the Interleukin-6 gene using adenovirus vector.
    Tanaka F; Abe M; Akiyoshi T; Nomura T; Sugimachi K; Kishimoto T; Suzuki T; Okada M
    Cancer Res; 1997 Apr; 57(7):1335-43. PubMed ID: 9102222
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Anti-metastatic effect of vascular endothelial growth factor receptor 2 extracellular domain gene-modified dendritic cell vaccination in murine model with experimental pulmonary metastasis].
    Pan JP; Weng YS; Wu QQ
    Zhonghua Zhong Liu Za Zhi; 2006 Sep; 28(9):646-9. PubMed ID: 17274366
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Identification of an interferon-gamma-inducible carcinoembryonic antigen (CEA) CD8(+) T-cell epitope, which mediates tumor killing in CEA transgenic mice.
    Schmitz J; Reali E; Hodge JW; Patel A; Davis G; Schlom J; Greiner JW
    Cancer Res; 2002 Sep; 62(17):5058-64. PubMed ID: 12208761
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The duration of TCR/pMHC interactions regulates CTL effector function and tumor-killing capacity.
    Riquelme E; Carreño LJ; González PA; Kalergis AM
    Eur J Immunol; 2009 Aug; 39(8):2259-69. PubMed ID: 19637198
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Decreased tumor surveillance after adoptive T-cell therapy.
    Matter M; Pavelic V; Pinschewer DD; Mumprecht S; Eschli B; Giroglou T; von Laer D; Ochsenbein AF
    Cancer Res; 2007 Aug; 67(15):7467-76. PubMed ID: 17671217
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.